{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:35:16Z","timestamp":1773322516609,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>It has not been elucidated whether incretins affect insulin clearance in type 2 diabetes (T2D). We aimed exploring possible associations between insulin clearance and endogenously secreted or exogenously administered incretins in T2D patients. Twenty T2D patients were studied (16 males\/4 females, 59\u2009\u00b1\u20092\u00a0years (mean\u2009\u00b1\u2009standard error), BMI\u2009=\u200931\u2009\u00b1\u20091\u00a0kg\/m<jats:sup>2<\/jats:sup>, HbA1c\u2009=\u20097.0\u2009\u00b1\u20090.1%). Patients were treated with metformin, sitagliptin, metformin\/sitagliptin combination, and placebo (randomized order). On each treatment period, oral and isoglycemic intravenous glucose infusion tests were performed (OGTT, IIGI, respectively). We also studied twelve T2D patients (9 males\/3 females, 61\u2009\u00b1\u20093\u00a0years, BMI\u2009=\u200930\u2009\u00b1\u20091\u00a0kg\/m<jats:sup>2<\/jats:sup>, HbA1c\u2009=\u20097.3\u2009\u00b1\u20090.4%) that underwent infusion of GLP-1(7\u201336)-amide, GIP, GLP-1\/GIP combination, and placebo. Plasma glucose, insulin, C-peptide, and incretins were measured. Insulin clearance was assessed as insulin secretion to insulin concentration ratio. In the first study, we found OGTT\/IIGI insulin clearance ratio weakly inversely related to OGTT\/IIGI total GIP and intact GLP-1 (R<jats:sup>2<\/jats:sup>\u2009=\u20090.13,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.02). However, insulin clearance showed some differences between sitagliptin and metformin treatment (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.02). In the second study we found no difference in insulin clearance following GLP-1 and\/or GIP infusion (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.5). Thus, our data suggest that in T2D there are no relevant incretin effects on insulin clearance. Conversely, different antidiabetic treatments may determine insulin clearance variations.<\/jats:p>","DOI":"10.1038\/s41598-022-06402-5","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T11:03:01Z","timestamp":1644922981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Insulin clearance and incretin hormones following oral and \u201cisoglycemic\u201d intravenous glucose in type 2 diabetes patients under different antidiabetic treatments"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3466-5900","authenticated-orcid":false,"given":"Andrea","family":"Tura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"G\u00f6bl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irfan","family":"Vardarli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Pacini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Nauck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"6402_CR1","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.2337\/db15-1373","volume":"65","author":"DC Polidori","year":"2016","unstructured":"Polidori, D. C., Bergman, R. N., Chung, S. T. & Sumner, A. E. Hepatic and extrahepatic insulin clearance are differentially regulated: results from a novel model-based analysis of intravenous glucose tolerance data. Diabetes 65, 1556\u20131564 (2016).","journal-title":"Diabetes"},{"key":"6402_CR2","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.2337\/dc20-0750","volume":"43","author":"F Piccinini","year":"2020","unstructured":"Piccinini, F. & Bergman, R. N. The measurement of insulin clearance. Diabetes Care 43, 2296\u20132302 (2020).","journal-title":"Diabetes Care"},{"key":"6402_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2337\/db19-1152","volume":"70","author":"A Gastaldelli","year":"2021","unstructured":"Gastaldelli, A., Ghani, M. A. & DeFronzo, R. A. Adaptation of insulin clearance to metabolic demand is a key determinant of glucose tolerance. Diabetes 70, 377\u2013385 (2021).","journal-title":"Diabetes"},{"key":"6402_CR4","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1210\/clinem\/dgab344","volume":"106","author":"A Galderisi","year":"2021","unstructured":"Galderisi, A. et al. Early impairment of insulin sensitivity, \u03b2-cell responsiveness, and insulin clearance in youth with stage 1 type 1 diabetes. J. Clin. Endocrinol. Metab. 106, 2660\u20132669 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"6402_CR5","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.numecd.2020.04.004","volume":"30","author":"A Tura","year":"2020","unstructured":"Tura, A. et al. Insulin clearance is altered in women with a history of gestational diabetes progressing to type 2 diabetes. Nutr. Metab. Cardiovasc. Dis. 30, 1272\u20131280 (2020).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"6402_CR6","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.2337\/db21-0227","volume":"70","author":"A Tura","year":"2021","unstructured":"Tura, A. et al. Profiles of glucose metabolism in different prediabetes phenotypes, classified by fasting glycemia, 2-hour OGTT, glycated hemoglobin, and 1-hour OGTT: an IMI DIRECT study. Diabetes 70, 2092\u20132106 (2021).","journal-title":"Diabetes"},{"key":"6402_CR7","doi-asserted-by":"publisher","first-page":"22453","DOI":"10.1038\/s41598-020-80581-x","volume":"10","author":"E Randrianarisoa","year":"2020","unstructured":"Randrianarisoa, E. et al. Reduced insulin clearance is linked to subclinical atherosclerosis in individuals at risk for type 2 diabetes mellitus. Sci. Rep. 10, 22453. https:\/\/doi.org\/10.1038\/s41598-020-80581-x (2020).","journal-title":"Sci. Rep."},{"key":"6402_CR8","doi-asserted-by":"publisher","first-page":"e0166263","DOI":"10.1371\/journal.pone.0166263","volume":"11","author":"A Labadzhyan","year":"2016","unstructured":"Labadzhyan, A. et al. Insulin clearance is associated with hepatic lipase activity and lipid and adiposity traits in Mexican Americans. PLoS ONE 11, e0166263. https:\/\/doi.org\/10.1371\/journal.pone.0166263 (2016).","journal-title":"PLoS ONE"},{"key":"6402_CR9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.atherosclerosis.2013.06.011","volume":"22","author":"MA Marini","year":"2013","unstructured":"Marini, M. A. et al. Insulin clearance is associated with carotid artery intima-media thickness. Atherosclerosis 22, 453\u2013458 (2013).","journal-title":"Atherosclerosis"},{"key":"6402_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/dom.12049","volume":"15","author":"CC Lee","year":"2013","unstructured":"Lee, C. C. et al. Components of metabolic syndrome and 5-year change in insulin clearance: the insulin resistance atherosclerosis study. Diabetes Obes. Metab. 15, 441\u2013447 (2013).","journal-title":"Diabetes Obes. Metab."},{"key":"6402_CR11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.0954-6820.1979.tb00720.x","volume":"624","author":"OK Faber","year":"1979","unstructured":"Faber, O. K., Madsbad, S., Kehlet, H. & Binder, C. Pancreatic beta cell secretion during oral and intravenous glucose administration. Acta Med. Scand. Suppl. 624, 61\u201364 (1979).","journal-title":"Acta Med. Scand. Suppl."},{"key":"6402_CR12","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/bmj.286.6369.921","volume":"286","author":"OM Gibby","year":"1983","unstructured":"Gibby, O. M. & Hales, C. N. Oral glucose decreases hepatic extraction of insulin. Br. Med. J. 286, 921\u2013923 (1983).","journal-title":"Br. Med. J."},{"key":"6402_CR13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.2337\/diab.32.5.436","volume":"32","author":"S Madsbad","year":"1983","unstructured":"Madsbad, S., Kehlet, H., Hilsted, J. & Tronnier, B. Discrepancy between plasma C-peptide and insulin response to oral and intravenous glucose. Diabetes 32, 436\u2013438 (1983).","journal-title":"Diabetes"},{"key":"6402_CR14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1210\/jcem-63-2-492","volume":"63","author":"MA Nauck","year":"1986","unstructured":"Nauck, M. A. et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. 63, 492\u2013498 (1986).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"6402_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/BF02427280","volume":"29","author":"M Nauck","year":"1986","unstructured":"Nauck, M., St\u00f6ckmann, F., Ebert, R. & Creutzfeldt, W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29, 46\u201352 (1986).","journal-title":"Diabetologia"},{"key":"6402_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2337\/dc18-1036","volume":"42","author":"A Shah","year":"2019","unstructured":"Shah, A. et al. Insulin clearance after oral and intravenous glucose following gastric bypass and gastric banding weight loss. Diabetes Care 42, 311\u2013317 (2019).","journal-title":"Diabetes Care"},{"key":"6402_CR17","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1007\/s00125-020-05157-w","volume":"63","author":"G Mingrone","year":"2020","unstructured":"Mingrone, G. et al. Insulin sensitivity depends on the route of glucose administration. Diabetologia 63, 1382\u20131395 (2020).","journal-title":"Diabetologia"},{"key":"6402_CR18","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.2337\/diabetes.53.9.2359","volume":"53","author":"NN Rudovich","year":"2004","unstructured":"Rudovich, N. N., Rochlitz, H. J. & Pfeiffer, A. F. Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients. Diabetes 53, 2359\u20132365 (2004).","journal-title":"Diabetes"},{"key":"6402_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00125-013-3134-3","volume":"57","author":"SH Kim","year":"2014","unstructured":"Kim, S. H. et al. Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study. Diabetologia 57, 455\u2013462 (2014).","journal-title":"Diabetologia"},{"key":"6402_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0167-0115(02)00297-5","volume":"113","author":"JJ Meier","year":"2003","unstructured":"Meier, J. J. et al. The reduction in hepatic insulin clearance after oral glucose is not mediated by gastric inhibitory polypeptide (GIP). Regul. Pept. 113, 95\u2013100 (2003).","journal-title":"Regul. Pept."},{"key":"6402_CR21","doi-asserted-by":"publisher","first-page":"E849","DOI":"10.1152\/ajpendo.00289.2007","volume":"293","author":"JJ Meier","year":"2007","unstructured":"Meier, J. J., Holst, J. J., Schmidt, W. E. & Nauck, M. A. Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans. Am. J. Physiol. Endocrinol. Metab. 293, E849\u2013E856 (2007).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"6402_CR22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","volume":"4","author":"MA Nauck","year":"2016","unstructured":"Nauck, M. A. & Meier, J. J. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 4, 525\u2013536 (2016).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"6402_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2337\/db13-0805","volume":"63","author":"I Vardarli","year":"2014","unstructured":"Vardarli, I., Arndt, E., Deacon, C. F., Holst, J. J. & Nauck, M. A. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and \u201cisoglycemic\u201d intravenous glucose. Diabetes 63, 663\u2013674 (2014).","journal-title":"Diabetes"},{"key":"6402_CR24","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.2337\/db10-1332","volume":"60","author":"N Mentis","year":"2011","unstructured":"Mentis, N. et al. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes 60, 1270\u20131276 (2011).","journal-title":"Diabetes"},{"key":"6402_CR25","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1210\/jc.2010-2178","volume":"96","author":"I Vardarli","year":"2011","unstructured":"Vardarli, I. et al. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as \u201cisoglycemic\u201d intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 96, 945\u2013954 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"6402_CR26","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/BF00401145","volume":"36","author":"MA Nauck","year":"1993","unstructured":"Nauck, M. A. et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7\u201336 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36, 741\u2013744 (1993).","journal-title":"Diabetologia"},{"key":"6402_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.regpep.2004.07.014","volume":"128","author":"MA Nauck","year":"2005","unstructured":"Nauck, M. A. & Meier, J. J. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul. Pept. 128, 135\u2013148 (2005).","journal-title":"Regul. Pept."},{"key":"6402_CR28","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00125-002-0878-6","volume":"45","author":"T Vilsb\u00f8ll","year":"2002","unstructured":"Vilsb\u00f8ll, T., Krarup, T., Madsbad, S. & Holst, J. J. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 45, 1111\u20131119 (2002).","journal-title":"Diabetologia"},{"key":"6402_CR29","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00125-014-3219-7","volume":"57","author":"A Tura","year":"2014","unstructured":"Tura, A., Muscelli, E., Gastaldelli, A., Ferrannini, E. & Mari, A. Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic. Diabetologia 57, 1199\u20131203 (2014).","journal-title":"Diabetologia"},{"key":"6402_CR30","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.numecd.2017.10.006","volume":"27","author":"A Tura","year":"2017","unstructured":"Tura, A. et al. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response. Nutr. Metab. Cardiovasc. Dis. 27, 1123\u20131129 (2017).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"Suppl 1","key":"6402_CR31","doi-asserted-by":"publisher","first-page":"S221","DOI":"10.2337\/diabetes.51.2007.S221","volume":"51","author":"A Mari","year":"2002","unstructured":"Mari, A., Tura, A., Gastaldelli, A. & Ferrannini, E. Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes 51(Suppl 1), S221\u2013S226 (2002).","journal-title":"Diabetes"},{"key":"6402_CR32","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s00125-018-4568-4","volume":"61","author":"A Tura","year":"2018","unstructured":"Tura, A. et al. Prediction of clamp-derived insulin sensitivity from the oral glucose insulin sensitivity index. Diabetologia 61, 1135\u20131141 (2018).","journal-title":"Diabetologia"},{"key":"6402_CR33","doi-asserted-by":"publisher","first-page":"611147","DOI":"10.3389\/fendo.2021.611147","volume":"12","author":"M Morettini","year":"2021","unstructured":"Morettini, M. et al. Mathematical model of glucagon kinetics for the assessment of insulin-mediated glucagon inhibition during an oral glucose tolerance test. Front. Endocrinol. (Lausanne) 12, 611147. https:\/\/doi.org\/10.3389\/fendo.2021.611147 (2021).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"6402_CR34","first-page":"E517","volume":"244","author":"E Ferrannini","year":"1983","unstructured":"Ferrannini, E. et al. Splanchnic and renal metabolism of insulin in human subjects: a dose-response study. Am. J. Physiol. 244, E517\u2013E527 (1983).","journal-title":"Am. J. Physiol."},{"key":"6402_CR35","doi-asserted-by":"publisher","first-page":"E966","DOI":"10.1152\/ajpendo.2001.281.5.E966","volume":"281","author":"A Tura","year":"2001","unstructured":"Tura, A., Ludvik, B., Nolan, J. J., Pacini, G. & Thomaseth, K. Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT. Am. J. Physiol. Endocrinol. Metab. 281, E966\u2013E974 (2001).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"6402_CR36","doi-asserted-by":"publisher","first-page":"R639","DOI":"10.1152\/ajpregu.00181.2017","volume":"314","author":"A Tura","year":"2018","unstructured":"Tura, A. et al. Increased insulin clearance in mice with double deletion of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors. Am. J. Physiol. Regul. Integr. Comp. Physiol. 314, R639\u2013R646 (2018).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"6402_CR37","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3390\/biomedicines9080973","volume":"9","author":"M Morettini","year":"2021","unstructured":"Morettini, M. et al. Hepatic and extrahepatic insulin clearance in mice with double deletion of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors. Biomedicines 9, 973. https:\/\/doi.org\/10.3390\/biomedicines9080973 (2021).","journal-title":"Biomedicines"},{"key":"6402_CR38","doi-asserted-by":"publisher","first-page":"R27","DOI":"10.1152\/ajpregu.00288.2018","volume":"316","author":"A Tura","year":"2019","unstructured":"Tura, A., Pacini, G., Yamada, Y., Seino, Y. & Ahr\u00e9n, B. Glucagon and insulin secretion, insulin clearance, and fasting glucose in GIP receptor and GLP-1 receptor knockout mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 316, R27\u2013R37 (2019).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"6402_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13098-019-0438-6","volume":"11","author":"C Anholm","year":"2019","unstructured":"Anholm, C. et al. Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease. Diabetol. Metab. Syndr. 11, 42. https:\/\/doi.org\/10.1186\/s13098-019-0438-6 (2019).","journal-title":"Diabetol. Metab. Syndr."},{"key":"6402_CR40","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/dom.13584","volume":"21","author":"K Cusi","year":"2019","unstructured":"Cusi, K. et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes. Metab. 21, 812\u2013821 (2019).","journal-title":"Diabetes Obes. Metab."},{"key":"6402_CR41","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.diabres.2018.05.017","volume":"142","author":"N Kurinami","year":"2018","unstructured":"Kurinami, N. et al. Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 142, 254\u2013263 (2018).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"6402_CR42","doi-asserted-by":"publisher","first-page":"258","DOI":"10.4158\/EP161323.OR","volume":"23","author":"E Ekholm","year":"2017","unstructured":"Ekholm, E. et al. Combined treatment with saxagliptin plus dapagliflozin reduces insulin levels by increased insulin clearance and improves \u03b2-cell function. Endocr. Pract. 23, 258\u2013265 (2017).","journal-title":"Endocr. Pract."},{"key":"6402_CR43","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/dom.12062","volume":"15","author":"L Ohlsson","year":"2013","unstructured":"Ohlsson, L. et al. Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects. Diabetes Obes. Metab. 15, 531\u2013537 (2013).","journal-title":"Diabetes Obes. Metab."},{"key":"6402_CR44","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2337\/dci20-0022","volume":"43","author":"WK Chung","year":"2020","unstructured":"Chung, W. K. et al. Precision medicine in diabetes: a consensus report from the American diabetes association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 43, 1617\u20131635 (2020).","journal-title":"Diabetes Care"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06402-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06402-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06402-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T14:16:08Z","timestamp":1700230568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06402-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6402"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-06402-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]},"assertion":[{"value":"6 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2510"}}